The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial
The Efficacy and Safety of Etrasimod in Mildly to Moderately Active Ulcerative Colitis: Results from the Phase 2 GLADIATOR Trial
Proactive Drug Monitoring Versus Clinically Based Dosing for Endoscopic Healing in Pediatric Crohn’s Disease Receiving Infliximab
Evaluation of oral nano-curcumin formulation effectiveness in patients with mild to moderate ulcerative colitis: a randomized, placebo-controlled, double-blind clinical trial
Azathioprine combined with either rifaximin (A microecological inhibitor) or infliximab for inflammatory bowel disease: Differential impacts on intestinal barrier function, inflammatory response and stress injury
Postoperative exclusive enteral nutrition as a bridging therapy to reduce endoscopic recurrence after intestinal resection in Crohn’s disease: A randomized controlled trial
Combined Upadacitinib and Vedolizumab as 8-Week Induction Therapy for Moderate-to-Severe Ulcerative Colitis: A Multicenter, Randomized Controlled Trial
The Effect of Dose Intensification After Secondary Loss of Response to Ustekinumab in Crohn’s Disease: Results of the REScUE Study
Hyperbaric oxygen therapy alters bowel perfusion and improves outcomes in patients with treatment-refractory ulcerative colitis: a prospective pilot trial
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
Ustekinumab therapy for moderately to severely active pediatric Crohn’s disease: UNITI Jr study safety and efficacy results in patients weighing at least 40 kg